Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 0.53 |
| ▸ | MMP9 | P14780 | 20/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728143 | 0.89 | MMP2 (0.57) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL726770 | 0.87 | MMP2 (0.69) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6689685 | 0.87 | MMP2 (0.39) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6442962 | 0.86 | MMP2 (0.55) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6449006 | 0.86 | MMP2 (0.53) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6462509 | 0.85 | MMP2 (0.60) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL2532335 | 0.85 | MMP2 (0.67) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6690419 | 0.85 | MMP2 (0.46) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6443590 | 0.84 | MMP2 (0.51) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL6445502 | 0.82 | MMP2 (0.56) | MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044035-B2 | Pharmaceutical compositions of pyrimidine-2,4,6-triones | UNIVERSITE DE LIEGE (BE) | 2011-10-25 | — | — | US | claimed |
| JP-4787240-B2 | — | — | 2011-10-05 | — | — | JP | claimed |
| US-20100261672-A1 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES | UNIVERSITE DE LIEGE (BE) | 2010-10-14 | — | — | US | claimed |
| EP-1737464-B1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20070191404-A1 | Pharmaceutical compositions of pyrimidine-2,4,6-triones | HOFFMANN-LA ROCHE INC. | 2007-08-16 | — | — | US | claimed |
| EP-1735007-A2 | CYCLODEXTRIN INCLUSION COMPLEXES OF PYRIMIDINE-2,4,6-TRIONES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097058-A2 | CYCLODEXTRIN INCLUSIONS COMPLEXES OF PYRIMIDINE-2,4,6-TRIONES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-20 | — | — | WO | claimed |
| EP-1226128-B1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2005-02-23 | — | — | EP | claimed |
| WO-2004084902-A1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT OF CHRONIC WOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | claimed |
| US-6498252-B1 | Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds | HOFFMANN-LA ROCHE INC. | 2002-12-24 | — | — | US | claimed |
| EP-1226128-A1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-31 | — | — | EP | claimed |
| WO-2001025217-A1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-12 | — | — | WO | claimed |
| US-8044035-B2 | Pharmaceutical compositions of pyrimidine-2,4,6-triones | UNIVERSITE DE LIEGE (BE) | 2011-10-25 | — | — | US | disclosed |
| US-20100261672-A1 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES | UNIVERSITE DE LIEGE (BE) | 2010-10-14 | — | — | US | disclosed |
| EP-1737464-B1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT AND PREVENTION OF BRONCHIAL INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-20070225253-A1 | Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | US | disclosed |
| EP-1226128-B1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2005-02-23 | — | — | EP | disclosed |
| WO-2004110457-A1 | MATRIX METALLOPROTEINASES INHIBITORS FOR THE STIMULATION AND PROTECTION OF BONE MARROW STEM CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004084902-A1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT OF CHRONIC WOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084903-A1 | USE OF A TRIOXOPYRIMIDINE FOR THE TREATMENT AND PREVENTION OF OCULAR PATHOLOGIC ANGIOGENESIS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191404-A1 | Pharmaceutical compositions of pyrimidine-2,4,6-triones | TK1, TYMP, TYMS | MMP2 4254/4885MMP9 4163/4885MMP8 3700/4885 |
| US-20100261672-A1 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES | TYMP, DPYD, TYMS | MMP2 4282/4885MMP9 4156/4885MMP8 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.